- Home
- MTLS vs LUNG Comparison
MTLS vs LUNG Comparison
Compare MTLS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTLS | LUNG |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.8M | 82.5M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MTLS | LUNG |
|---|---|---|
| Price | $5.65 | $1.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 157.0K | ★ 479.5K |
| Earning Date | 02-19-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $308,751,613.00 | $91,664,000.00 |
| Revenue This Year | $2.47 | $9.21 |
| Revenue Next Year | $6.98 | $5.03 |
| P/E Ratio | $64.12 | ★ N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $3.93 | $1.31 |
| 52 Week High | $9.69 | $9.37 |
Technical Indicators
Market Signals| Indicator | MTLS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 35.31 |
| Support Level | $5.44 | $1.92 |
| Resistance Level | $5.80 | $2.03 |
| Average True Range (ATR) | 0.23 | 0.13 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 29.03 | 0.97 |
Price Performance
Historical ComparisonAbout MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.